AMAG Pharmaceuticals is providing this information on cancer disease state because we believe it is important for our field sales team to possess a strong understanding of the Hematology/Oncology market.  The Hem/Onc market is where the majority of utilization occurs for our product portfolio.  AMAG does not have an indication and is not part of the cancer regimen although some cancer patients may have symptoms of IDA or oral mucositis which do fall into our approved indications for Feraheme and MuGard.

This information is composed of the Backgrounder content and a Videos Gallery.  After viewing this content, please take the Module Review Quiz to evaluate your understanding of the material.

TODO: Add contents table with links here